Epilepsy – Epidemiology – Europe

Clarivate Epidemiology’s coverage of epilepsy comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of epilepsy for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the major mature pharmaceutical markets.

Clarivate Epidemiology’s epilepsy forecast will answer the following questions:

• Of all people diagnosed with epilepsy, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of epilepsy over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following subpopulations:

• Diagnosed prevalence of Lennox-Gastaut cases by intractable epilepsy.
• Diagnosed prevalent cases by risk of acute repetitive seizures.
• Diagnosed prevalent cases by drug-treatment status.
• Diagnosed prevalent cases by seizure level.
• Diagnosed prevalence of Lennox-Gastaut cases by type of seizure.
• Diagnosed prevalence of Lennox-Gastaut cases by status epilepticus.
• Drug-treated prevalent cases by drug-resistance status.
• Scn1a mutation status.
• Status epilepticus status.

Note: Coverage may vary by country.